MET and cancer: INCB28060 is a small molecule inhibitor with picomolar enzymatic potency and is highly specific for MET with more than 10,000-fold selectivity over a large panel of other human kinases.84 Functionally, INCB28060 showed potent inhibition of MET-mediated signaling cascades in various cancer cells, and preferentially inhibited tumors with MET amplification.84,85 Currently, a phase I clinical trial is evaluating the safety and efficacy of the combination of INC28060 and bevacizumab in GBM patients with previous treatment and those with unresectable GBM (NCT02386826).